Strategic Expansion Arkstone has pursued international partnerships and platform expansion, including a recent Peruvian expansion with Neslab and collaborations with UNG, signaling opportunities to upsell clinical decision support and antimicrobial stewardship solutions in new markets and institutions.

AI Driven CDS The launch of the Expert-in-the-Loop ML and AI-powered clinical decision platform positions Arkstone as a provider of advanced, AI-enhanced antimicrobial stewardship and infectious disease guidance, presenting cross-sell potential to healthcare providers seeking high-precision decision support.

Acquisition Backing Arkstone is now majority-owned by Archimed, a global healthcare private equity firm, which can facilitate enterprise sales cycles, channel partnerships, and faster procurement conversations with large health systems and multi-site networks.

Financial Footing With reported revenue in the range of tens of millions, Arkstone demonstrates market traction that can be leveraged in ROI-focused sales pitches emphasizing cost containment, drug pricing information integration, and value-based antimicrobial stewardship outcomes.

Platform Growth Recent platform enhancements such as OneChoice drug cost information and expanded lab guidance capabilities indicate opportunities to upsell to existing customers and expand into new departments within hospitals and biotech labs that require integrated cost data, resistance gene profiling, and comprehensive antimicrobial guidance.